Skip to main content
. 2007 Jul 10;97(4):494–501. doi: 10.1038/sj.bjc.6603885

Figure 6.

Figure 6

Cetuximab- and/or trastuzumab-mediated ADCC for oesophageal SCC cell lines. Oesophageal SCC cell lines with various levels of EGFR and HER-2 expression (TE3, KYSE50, and TE4) were analysed for ADCC derived from healthy donor’s PBMC in various dose combinations of cetuximab, trastuzumab, and control mAb by the 6-h 51Cr release assay. E : T, effector/target ratios.